KVUE Stock Recent News

Chevron can grow its cash flow at a strong rate even if oil prices cool off. Kenvue is in an excellent position to grow shareholder value as an independent company.

JNJ stock occupies a top spot in many portfolios due to its consistent performance and low volatility. But should we really and readily accept JNJ as a SWAN stock? A fresh look at Johnson & Johnson is warranted, especially in light of the split-off of its Consumer Health segment (Kenvue stock) and amid the ongoing talc litigation. I share my view on JNJ's two remaining segments, their future prospects, and the decline in cash flow due to the split-off of the Consumer Health segment.

While many, if not most investors, appear bullish about the market's prospects this year, it's never a bad time to consider long-term dividend stocks. By that, we're talking about profitable, relevant enterprises that you can trust.

While the calendar was quiet this past week, six IPOs joined the pipeline, two of which we estimate could raise $1 billion or more. Three biotechs filed to raise $100 million.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce financial results for the fourth quarter and full year ending December 31, 2023, on February 8, 2024.

One of the main themes of 2023 may be relief – that is, relief that we avoided a downcycle – and so it begs the question: why talk about 2024 recession worries? More to the point, why deal with recession stocks?

Some investments just look after themselves. They are “set it and forget it” kind of stocks.

A ruling hurts litigation against Kenvue that alleges a link between prenatal exposure to the company's Tylenol and autism spectrum disorder or ADHD.

Shares of Tylenol maker Kenvue Inc. KVUE, +0.10% gained more than 5% premarket on Tuesday after a federal court judge in New York ruled that plaintiffs' expert testimony will be blocked in a case involving product-liability claims against the manufacturers of Tylenol and generic acetaminophen. Judge Denise Cote of U.S. District Court for the Southern District of New York on Monday granted the defendants' motion to exclude plaintiffs' expert opinions on whether in-utero exposure to acetaminophen could cause children to develop autism spectrum disorder and attention deficit hyperactivity disorder.

In May, Kenvue Inc. (KVUE, Financial) successfully concluded its separation from Johnson & Johnson (JNJ, Financial); however, its stock has experienced a decline about 25% since the completion of this process, likely driven by Investors nervousness about Tylenol litigation. The drop in value appears to be excessive even if the company may have to settle some lawsuits.